Sort by
Reactive Power Collaborative Control Strategy and Verification Method for Suppressing Voltage Oscillation in Renewable Energy Clusters
Yanzhang Liu
,Lingzhi Zhu
,Minhui Qian
,Chen Jia
Posted: 05 January 2026
Effects of the Synbiotic Formulation EDC-HHA01 on Glucose Regulation in Adults with Type 2 Diabetes and Prediabetes : A Randomized, Placebo-Controlled Study
Gissel García
,María del Carmen Campos
,Josanne Soto
,Antonio Diaz
,Emilio Buchaca
,Duniesky Martínez
,Mirka Bernal
,Viviana Escobar
,Lais Rodríguez
,Eduardo Valdés
+4 authors
Posted: 05 January 2026
Potential of Radiomics to Improve Diagnostic Accuracy of Mammograms and Personalise Patient Management in Breast Cancer
Yauhen Statsenko
,Darya Smetanina
,Aidar Kashapov
,Roman Voitetskii
,Milos Ljubisavljevic
Posted: 05 January 2026
Accuracy and Precision of a Novel Digital Impression Workflow with Artificial Intelligence Based Integrated Tool for All-on-X Rehabilitations: A Multicenter Prospective Cohort Study
Marco Tallarico
,Mohamed Fathy El Ashry
,Carlotta Cacciò
,Mohammad Qaddomi
,Ahmed Ashraf
,Mayar Omar
,Dalia Ghalwash
,Francesco Mattia Ceruso
,Silvio Mario Meloni
,David Chong
Posted: 05 January 2026
Tracking ESBL-Producing Escherichia coli Across Municipal Wastewater and Farm Ecosystems: A One Health Investigation
Jordan Deutschlander
,Isaiah Taylor
,Stacious Ward-swan
,Deepa Struble
,Katrina Edwards
,Yvette Wittenborn
,Giannah Dowen
,Lyndy Harden
,Rhonda Locklear
,Mitsu Suyemoto
+1 authors
Posted: 05 January 2026
Triangulated Analytical Framework for Sustainable FinTech Model: The Case of Latvia
Zakia Siddiqui
,Claudio Andres Rivera
Posted: 05 January 2026
Proteomic Profiling of the Hippocampus of Rats Subjected to the Pilocarpine Model of Epilepsy
Daniele Suzete Persike
,Mariana Leão de Lima Stein
,Maria José Da Silva Fernandes
Posted: 05 January 2026
Citing the Unseen: AI Hallucinations in Tax and Legal Practice a Comparative Analysis of Professional Responsibility, Procedural Legitimacy, and Sanctions
Pramod Kumar Siva
Posted: 05 January 2026
A Methodological Framework for Rigorous Meta Ads Experimentation
Umer Hajam
Posted: 05 January 2026
Non-Intrusive Multimodal AI Framework for Detecting Hazardous Misdeclared Cargo in Maritime Containers
Manikandan Chandran
Posted: 05 January 2026
When AI Reviews Science: Can We Trust the Referee?
Jialiang Wang
,Yuchen Liu
,Hang Xu
,Kaichun Hu
,Shimin Di
,Wangze Ni
,Linan Yue
,Min-Ling Zhang
,Kui Ren
,Lei Chen
Posted: 05 January 2026
Dense Local Azimuth-Elevation Map for the Integration of GIS Data and Camera Images
Gilbert Maître
Posted: 05 January 2026
Generalized Dynamical Model for the Drag Coefficient of Fixed and Moving Cylindrical Bodies
Osama A. Marzouk
Posted: 05 January 2026
The Information Dynamics of Generative Diffusion
Dejan Stančević
,Luca Ambrogioni
Posted: 05 January 2026
Positive and Negative Selection of Extracellular Vesicle-Based Biomarkers: Insights from L1CAM Immunocapture and Emerging Immunodepletion Strategies
Adam P.S. Bennett
Posted: 05 January 2026
SORT-AI: Interconnect Stability and Cost per Performance in Large-Scale AI Infrastructure—A Structural Analysis of Runtime Instability in Distributed Systems
Gregor Herbert Wegener
Posted: 05 January 2026
Intraclonal Enrichment of IL-23 Receptor Complex Expression in the Proliferative Fraction of Chronic Lymphocytic Leukemia
Martina Cardillo
,Fabiana Ferrero
,Nadia Bertola
,Ennio Nano
,Rosanna Massara
,Maria Cristina Capra
,Daniele Reverberi
,Monica Colombo
,Vanessa Cossu
,Fabio Ghiotto
+9 authors
Chronic lymphocytic leukemia (CLL) is a dynamic malignancy in which intraclonal subfractions differ in activation history and responsiveness to microenvironmental signals. Here, we investigated the expression and inducibility of IL-12 family receptor subunits (IL-23R, IL-12Rβ1, IL-12Rβ2) and the related receptor complexes in recirculating CLL cells, with a focus on CXCR4/CD5-defined fractions: the proliferative fraction (PF; CXCR4^dim/CD5^bright; most recently divided, tissue-emigrated cells) and the resting fraction (RF; CXCR4^bright/CD5^dim; older, quiescent cells). At baseline, IL-12Rβ1 was enriched in the PF and was associated with a higher proportion of cells expressing IL-23R and IL-12R receptor complexes. Concomitantly, RT-qPCR disclosed higher IL-12Rβ1 mRNA levels. Following antigen-independent activation with CpG or CpG + IL-15, there was a marked increase of IL-23R and IL-12Rβ1 but not of IL-12Rβ2 surface expression, resulting in preferential upregulation of the IL-23R complex over the IL-12R complex. Fraction-specific analyses showed stronger induction of IL-23R and IL-23R complex expression in PF compared with RF. These findings identify an intraclonal bias toward IL-23 responsiveness in the CLL cells with a phenotype of recently divided, tissue-emigrated cells and suggest the IL-23/IL-23R axis as a potential therapeutic target.
Chronic lymphocytic leukemia (CLL) is a dynamic malignancy in which intraclonal subfractions differ in activation history and responsiveness to microenvironmental signals. Here, we investigated the expression and inducibility of IL-12 family receptor subunits (IL-23R, IL-12Rβ1, IL-12Rβ2) and the related receptor complexes in recirculating CLL cells, with a focus on CXCR4/CD5-defined fractions: the proliferative fraction (PF; CXCR4^dim/CD5^bright; most recently divided, tissue-emigrated cells) and the resting fraction (RF; CXCR4^bright/CD5^dim; older, quiescent cells). At baseline, IL-12Rβ1 was enriched in the PF and was associated with a higher proportion of cells expressing IL-23R and IL-12R receptor complexes. Concomitantly, RT-qPCR disclosed higher IL-12Rβ1 mRNA levels. Following antigen-independent activation with CpG or CpG + IL-15, there was a marked increase of IL-23R and IL-12Rβ1 but not of IL-12Rβ2 surface expression, resulting in preferential upregulation of the IL-23R complex over the IL-12R complex. Fraction-specific analyses showed stronger induction of IL-23R and IL-23R complex expression in PF compared with RF. These findings identify an intraclonal bias toward IL-23 responsiveness in the CLL cells with a phenotype of recently divided, tissue-emigrated cells and suggest the IL-23/IL-23R axis as a potential therapeutic target.
Posted: 05 January 2026
Safety and Efficacy of Mosunetuzumab: Experience in the A.O. Card G. Panico
Giulio Turco
,Donatella Tarantino
,Antonietta Giuseppa Ferraro
,Giuseppina Greco
,Domenico Tricarico
Follicular lymphoma (FL) is the second most common form of non-Hodgkin’s lymphoma (NHL) and accounts for about 5% of all hematological malignancies. Despite therapeutic advances, FL follicular lymphoma remains an incurable disease, with frequent relapses and increasingly shorter disease control intervals. Bispecific antibodies (bsAbs) are molecules that target two different epitopes or antigens. The mechanism of action is determined by the molecular targets and structure of the bsAbs. Several bsAbs have already changed the therapeutic landscape of hematological malignancies and some solid tumors. In particular, in this article we review the general principles on follicular lymphoma and established and innovative therapies including bsAbs, in particular the bsAb mosunetuzumab, a new bispecific antibody that acts on CD3 epitopes of T lymphocytes and CD20 epitopes of B lymphocytes with the aim of inducing T lymphocyte-mediated elimination of malignant B lymphocytes, its safety and efficacy with the analysis of no. 3 patients who completed treatment with the drug mosunetuzumab in the A.O. Pia Fondazione di Culto e Religione ‘Card. G. Panico’, Tricase (Lecce).
Follicular lymphoma (FL) is the second most common form of non-Hodgkin’s lymphoma (NHL) and accounts for about 5% of all hematological malignancies. Despite therapeutic advances, FL follicular lymphoma remains an incurable disease, with frequent relapses and increasingly shorter disease control intervals. Bispecific antibodies (bsAbs) are molecules that target two different epitopes or antigens. The mechanism of action is determined by the molecular targets and structure of the bsAbs. Several bsAbs have already changed the therapeutic landscape of hematological malignancies and some solid tumors. In particular, in this article we review the general principles on follicular lymphoma and established and innovative therapies including bsAbs, in particular the bsAb mosunetuzumab, a new bispecific antibody that acts on CD3 epitopes of T lymphocytes and CD20 epitopes of B lymphocytes with the aim of inducing T lymphocyte-mediated elimination of malignant B lymphocytes, its safety and efficacy with the analysis of no. 3 patients who completed treatment with the drug mosunetuzumab in the A.O. Pia Fondazione di Culto e Religione ‘Card. G. Panico’, Tricase (Lecce).
Posted: 04 January 2026
Retrospective Cohort Study: Predictors of One-Year Mortality in Hemodialysis Patients with End-Stage Renal Disease at a Kenyan County Hospital
Felix Pius Omullo
,Thomas Kimanzi Kitheghe
,Maureen Mueni Mark
,Allan Kariuki Ng'a ng'a
,Magdalene Wanjiru Parsimei
,Wambugu Charles Kanyi
,Ooko Anyang'o Emma
,Ismail Abdi Sheikh
,Joshua Macharia Gitimu
,Abel Mwangi Gakuya
+3 authors
Posted: 04 January 2026
Effects of a Proactive Driving Transition Class on Extending Safe Driving and Preparing for Life After Driving Cessation Among Older Drivers
Tsutomu Sasaki
,Kyohei Yamada
,Takeshi Yamakita
,Naoto Sakuta
,Hajime Yoshida
,Takeshi Tominaga
Posted: 04 January 2026
of 5,414